Biotech Startups

AlgaleX produces "Umamo," an umami-rich microalgae (Aurantiochytrium) cultivated by fermenting unused food resources such as discarded awamori lees, yielding a natural DHA-rich flavor ingredient sold as an alternative to kombu and bonito. Founded by a former trading company businessperson and University of Tsukuba academics, the company develops algae fermentation technology aimed at supplying protein and omega-3 nutrients without depleting fish stocks, operating from Okinawa, Japan.

2 investors

Algenie develops helical photobioreactor technology to lower the cost of algae production at scale, converting CO2 into raw materials for feed, fuel, plastics, and building materials. The company targets industrial and climate-tech applications, positioning algae as a sustainable, economically viable feedstock, and is based in Australia.

2 investors

Alia Therapeutics is a biotech company developing therapeutics based on gene-editing technology.

2 investors

Aliada Therapeutics was a Boston-based clinical-stage biotech developing its MODEL platform to transport therapeutic antibodies across the blood-brain barrier for CNS diseases. Its lead candidate, an anti-amyloid-beta antibody, targeted Alzheimer's disease.

2 investors

Aligned Bio develops nanowire-based biosensor platforms capable of detecting single molecules, serving customers in diagnostic and research applications. The company manufactures advanced sensors using proprietary methods for organizing and functionalizing nanowires on various substrates.

2 investors

Alithea Genomics develops RNA sequencing technologies and platforms that enable pharmaceutical, agritech, cosmetics, and academic teams to generate large-scale transcriptomic datasets for compound screening, crop engineering, and ingredient development. The company's plate-based, high-throughput solutions reduce costs, hands-on time, and environmental impact compared to standard RNA-seq practices.

2 investors

AlkaLi Labs develops microbial hyperaccumulators that extract critical minerals, including lithium, from industrial waste streams to supply materials needed for green energy hardware and electrification. The company positions its approach as a low-impact alternative mining method sourcing minerals from dilute and contaminated waste.

2 investors

ALLInBio develops a precision immunology approach to identify and treat patients genetically predisposed to rapid progression of chronic inflammatory diseases. The platform shifts treatment from symptom management to early intervention in at-risk populations.

2 investors

Allelica develops multi-ancestry polygenic risk scores and a cloud and on-premise software platform for clinical genomic risk prediction of common diseases. The platform is used by physicians and health systems in the US and internationally for earlier genomic risk stratification.

2 investors

A pharmaceutical and life sciences company developing drug pipelines and conducting research and innovation activities. Based in Shanghai, the company focuses on pharmaceutical development and external partnerships in the biotech sector.

2 investors

Allium Bio develops a co-culturing system that grows multiple species—such as algae, fungi, and yeasts—together to produce food ingredients that combine their nutritional properties like proteins, fats, and vitamins. The company aims to design sustainable co-cultured ingredients for the food industry using faster modeling in place of lengthy research.

2 investors

Allorion Therapeutics is a drug development company focused on advancing new therapeutics. The page presents its leadership and scientific founders drawn from academic and medical research institutions.

2 investors

Allos uses causal AI modeling to optimize pharmaceutical drug formulation and reformulation, mapping chemistry, process variables, and performance data to reduce failed experiments and shorten timelines. It serves innovator and generic drug companies, coordinating CROs and CDMOs to take a molecule from modeling through manufacturing.

2 investors

Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy acting at mGluR5, currently in Phase 1b clinical development for Alzheimer's disease.

2 investors

Aloe Therapeutics develops AIM-001, a localized cell-based immunotherapy implanted at tumor sites during surgery to activate the immune system and improve response to checkpoint immunotherapy in patients with advanced solid tumors.

2 investors

ALORA develops gene-edited, non-GMO crop traits that change how plants allocate energy, directing it toward yield rather than stress defense to maintain productivity under heat and soil salinity. First proven in rice, the company validates its traits through greenhouse research and field trials, with operations at the Norwich Research Park in the United Kingdom.

2 investors

Alpha Tau Medical develops Alpha DaRT, a technology platform for cancer treatment using targeted alpha radiation therapy across multiple cancer types including skin, pancreatic, brain, lung, and prostate cancers at various clinical stages.

2 investors

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision. It operates in the oncology and precision medicine space.

2 investors

Alphabiome builds an AI layer for drug development that analyzes raw bacterial, viral, and host DNA lacking a reference map to predict which therapies work in which patients. Its technology is applied to precision medicine, spanning multiple indications and therapies.

2 investors

AlphaNavi Pharma is a pharmaceutical company developing new drugs (Nav channel inhibitors) for patients suffering from chronic pain and neurological disorders. It conducts in-house research and development in collaboration with academia, companies, and investors in Japan and abroad.

2 investors

AlphaRose develops genetic technologies and treatments for children with rare genetic diseases, aiming to make and commercialize such medicines at scale. It targets patients underserved by the current healthcare model for rare genetic conditions.

2 investors

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites. The company's lead program is in a randomized Phase 2b trial for newly diagnosed glioblastoma.

2 investors

2 investors

Atlas AI provides wet-lab, bioinformatics, and AI services on a modular, expert-led basis, helping clients with experimental execution, data generation, analytical pipelines, and deployed software systems. It serves partners across biotech, healthtech, and industrial domains, from early-stage research through applied R&D and pre-industrial development.

2 investors